Appendix 4c quarterly activity report for quarter ended december 31, 2023

New york, jan. 30, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended december 31, 2023. mesoblast chief executive silviu itescu said: “it has been a very busy quarter in which we have made substantial operational progress across our three lead phase 3 assets.
MESO Ratings Summary
MESO Quant Ranking